Identification of Phenoxyalkylbenzimidazoles with Antitubercular Activity.

@article{Chandrasekera2015IdentificationOP,
  title={Identification of Phenoxyalkylbenzimidazoles with Antitubercular Activity.},
  author={N. S. Chandrasekera and Torey Alling and M. Bailey and M. Files and J. Early and J. Ollinger and Y. Ovechkina and T. Masquelin and P. Desai and J. Cramer and P. Hipskind and J. Odingo and T. Parish},
  journal={Journal of medicinal chemistry},
  year={2015},
  volume={58 18},
  pages={
          7273-85
        }
}
We conducted an evaluation of the phenoxyalkylbenzimidazole series based on the exemplar 2-ethyl-1-(3-phenoxypropyl)-1H-benzo[d]imidazole for its antitubercular activity. Four segments of the molecule were examined systematically to define a structure-activity relationship with respect to biological activity. Compounds had submicromolar activity against Mycobacterium tuberculosis; the most potent compound had a minimum inhibitory concentration (MIC) of 52 nM and was not cytotoxic against… Expand
Improved Phenoxyalkylbenzimidazoles with Activity against Mycobacterium tuberculosis Appear to Target QcrB
TLDR
The most potent compounds had minimum inhibitory concentrations against Mycobacterium tuberculosis in the low nanomolar range with very little cytotoxicity against eukaryotic cells as well as activity against intracellular bacteria. Expand
Benzimidazoquinazolines as new potent anti-TB chemotypes: Design, synthesis, and biological evaluation.
TLDR
In search for new molecular entities as anti-TB agents, the benzimidazoquinazoline polyheterocyclic scaffold has been designed adopting the scaffold hopping strategy and was found to be non-toxic against INH resistant Mtb strains. Expand
Synthesis and biological evaluation of novel triazole-biscoumarin conjugates as potential antitubercular and anti-oxidant agents
The synthesis of a new series of triazole-biscoumarin conjugates by using a molecular hybridization approach is described. The newly synthesized compounds 6a–k were evaluated for their in vitroExpand
Combinations of Respiratory Chain Inhibitors Have Enhanced Bactericidal Activity against Mycobacterium tuberculosis
TLDR
The potential for combination treatment targeting the ETC is highlighted and the development of PABs as part of a novel drug regimen against M. tuberculosis is supported. Expand
New structural classes of antituberculosis agents
TLDR
This review covers literature reports of the subsequent 10 years on the discovery of new structural classes of synthetic anti‐TB agents and divided new compounds in 38 structural classes, 368 structures, and 307 references. Expand
Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis.
TLDR
The discovery of two diverse lead series imidazo[1,2-a]pyridine ethers and squaramides as inhibitors of mycobacterial ATP synthesis is reported, establishing a robust structure-activity relationship of these two scaffolds, resulting in nanomolar potencies in an ATP synthesis inhibition assay. Expand
Design, synthesis, and biological evaluation of benzo[d]imidazole-2-carboxamides as new anti-TB agents.
TLDR
The determination and analysis of various physiochemical parameters revealed favorable druglike properties of the active compounds and highlight the discovery of benzimidazole-2-carboxamides for further development as new anti-TB agents. Expand
Phenoxyalkylimidazoles with an oxadiazole moiety are subject to efflux in Mycobacterium tuberculosis
TLDR
Two analogs containing an oxadiazole had improved potency in the presence of the efflux inhibitors reserpine and carbonyl cyanide m-chlorophenylhydrazine, whereas the potency of an analog with a diazole was not affected. Expand
Identification of 4-Amino-Thieno[2,3-d]Pyrimidines as QcrB Inhibitors in Mycobacterium tuberculosis
TLDR
A new series of antimycobacterial compounds, 4-amino-thieno[2,3-d]pyrimidines, that potently inhibit the growth of M. tuberculosis growth in vitro are reported. Expand
Novel MenA Inhibitors Are Bactericidal against Mycobacterium tuberculosis and Synergize with Electron Transport Chain Inhibitors
TLDR
It is shown that inhibitors of MenA, a component of the menaquinone biosynthetic pathway, are highly active against M. tuberculosis, supporting MenA as a viable target for drug treatment against this deadly pathogen. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 21 REFERENCES
A Trisubstituted Benzimidazole Cell Division Inhibitor with Efficacy against Mycobacterium tuberculosis
TLDR
It is demonstrated that SB-P17G-A20 has potency against M. tuberculosis clinical strains with varying susceptibility and efficacy in animal models of infection, and that trisubstituted benzimidazoles continue to be a platform for the development of novel inhibitors with efficacy. Expand
Synthesis, antibacterial and antitubercular activities of benzimidazole bearing substituted 2-pyridone motifs.
TLDR
A series of benzimidazole bearing 2-pyridones 5a-r were synthesized and evaluated for their in vitro antibacterial and antitubercular activity and it was observed that the compounds 5h, 5i, 5k, 5q and 5r were found to possess significant broad spectrum antibacterial activity. Expand
Design, synthesis and in vitro antiprotozoal activity of benzimidazole-pentamidine hybrids.
TLDR
A series of ten novel hybrids from benzimidazole and pentamidine prepared using a short synthetic route tested in vitro against the protozoa Trichomonas vaginalis, Giardia lamblia, Entamoeba histolytica, Leishmania mexicana, and Plasmodium berghei to provide new leads against protozoal diseases. Expand
Antiprotozoal activities of benzimidazoles and correlations with beta-tubulin sequence
TLDR
In vitro susceptibility data for Trichomonas vaginalis and G. lamblia is presented and in vitro activity of benzimidazoles against additional protozoan parasites is examined: little or no activity was observed against Entamoeba histolytica, Leishmania major, and AcanthamoebA polyphaga. Expand
Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing.
Type II topoisomerases are well conserved across the bacterial species, and inhibition of DNA gyrase by fluoroquinolones has provided an attractive option for treatment of tuberculosis (TB). However,Expand
Synthesis and antimycobacterial activity of 2-substituted halogenobenzimidazoles.
TLDR
A series of substituted 2-polyfluoroalkyl and 2-nitrobenzylsulphanyl benzimidazoles was synthesized and showed appreciable antimycobacterial activity, particularly 5,6-dichloro-2-nonafluorobutylbenzimidrazole (2h). Expand
Benzimidazole-based compounds kill Mycobacterium tuberculosis.
TLDR
The design, synthesis and structure-activity relationships of a series of benzimidazole-based compounds with activity against Mycobacterium tuberculosis in a replicating state, a physiologically-induced non-replicatingState, or both are described. Expand
Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action
TLDR
The mechanism of the antiviral effect of l-riboside 1263W94 is thus distinct from those of GCV and of BDCRB, including those resistant to ganciclovir, foscarnet, andBDCRB. Expand
Antimicrobial activity and a SAR study of some novel benzimidazole derivatives bearing hydrazone moiety.
TLDR
In this study 12 novel benzimidazole compounds bearing hydrazone moiety were synthesized in order to investigate their possible antibacterial and antifungal activity and a connection between antibacterial activity and electronic properties of the target compounds was determined. Expand
Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles.
TLDR
The activity of 35 against wild-type and resistant strains with amino acid substitution in RT is comparable to that of other nonnucleoside inhibitors currently undergoing clinical trials, most of which do not have the capacity to inhibit the variant forms of the enzyme. Expand
...
1
2
3
...